Arnould L et al. Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94(2):259-67. Abstract
BCIRG. Interim analysis of phase III study shows Taxotere® (docetaxel)-based chemotherapy regimens combined with Herceptin® (trastuzumab) significantly improved disease free survival in early-stage HER2-positive breast cancer. September 15, 2005. [press release]
Burstein HJ. The distinctive nature of HER2-positive breast cancer. N Engl J Med 2005;353(16):1652-4. No abstract available
Burstein HJ et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21(15):2889-95. Abstract
Carlson RW et al. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 2006;4(Suppl 1):1-26. Abstract
Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning? Clin Breast Cancer 2003;4(3):179-86. Abstract
Flaherty KT, Brose MS. Her-2 targeted therapy: Beyond breast cancer and trastuzumab. Curr Oncol Rep 2006;8(2):90-5. Abstract
Hicks DG et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: A fluorescence in situ hybridization study. Hum Pathol 2005;36(4):348-56. Abstract
Hillner BE. Clinical and cost-effectiveness implications of the adjuvant trastuzumab in HER2+ breast cancer trials. San Antonio Breast Cancer Symposium 2005;Abstract 5040.
Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353(16):1734-6. No abstract available
Hubbard SR. EGF receptor inhibition: Attacks on multiple fronts. Cancer Cell 2005;7(4):287-8. Abstract
Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract
Joensuu H et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: The FinHer Trial. San Antonio Breast Cancer Symposium 2005;Abstract 2.
Mamounas EP. Can we approach zero relapse in breast cancer? Oncologist 2005;10 (Suppl 2):9-17. Abstract
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.
Nahleh ZA, Jazieh AR. Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer. Am J Clin Oncol 2005;28(6):631-3. Abstract
Neyt M et al. An economic evaluation of Herceptin® in adjuvant setting: The Breast Cancer International Research Group 006 trial. Ann Oncol 2006;17(3):381-90. Abstract
Perez EA. Further analysis of NCCTG-N9831. Presentation. ASCO 2005. No abstract available
Perez EA et al. Exploratory analysis from NCCTG N9831: Do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? San Antonio Breast Cancer Symposium 2005;Poster 2038. Abstract
Perez EA et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Presentation. ASCO 2005;Abstract 556.
Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005a. No abstract available
Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005b;353(16):1659- 72. Abstract
Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium 2005;Poster 1045.
Ragaz J, Spinelli JJ. Cost-benefit estimates of adjuvant (Adj) trastuzumab (Herceptin, H) for early breast cancer (BrCa). San Antonio Breast Cancer Symposium 2005;Abstract 2029.
Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005a. No abstract available
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2- positive breast cancer. N Engl J Med 2005b;353(16):1673-84. Abstract
Slamon D et al. BCIRG 006 — Randomized Phase III trial comparing AC-T vs ACTH TCH in HER2 positive node positive or high risk node negative breast cancer. Presentation. NSABP meeting. September 2005. No abstract available
Slamon D et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: First interim efficacy analysis. Presentation. San Antonio Breast Cancer Symposium 2005. www.bcirg.org. Abstract 1
Slamon D et al, on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2005;Abstract 1.
Slamon DJ. Antibody-based therapeutics: More than a one-trick pony. Presentation. ASCO 2005. No abstract available
Sparano JA et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 48.
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
Toi M et al. Trastuzumab: Updates and future issues. Cancer Chemother Pharmacol 2005;56(Suppl 1):94-9. Abstract
Yang SX et al. Response in gene expression profile to bevacizumab treatment in patients with inf lammatory and locally advanced breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 2028.
|Terms and Conditions of Use and General Disclaimer
Copyright © 2006 Research To Practice. All Rights Reserved